evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

59 questions · 66 findings · 5 reviews · Skin

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 2 · 3%GRADE not reported 4 · 6.1%Very low 11 · 16.7%Low 31 · 47%Moderate 17 · 25.8%High 1 · 1.5%

Tacrolimus 0.1% vs vehicle

Primary: investigator‐rated good/excellent control of symptoms · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…

Topical calcineurin inhibitors: tacrolimus 0.1% ointment probably leads to higher primary: investigator‐rated good/excellent control of symptoms compared with vehicle (moderate certainty).

1 finding from 1 review

Tacrolimus 0.1% vs vehicle

Primary: participant‐rated good/excellent control of symptoms Not measured · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…

The review found no eligible studies for this question.

1 finding from 1 review

Tacrolimus 0.1% vs vehicle

Primary: adverse events ‐ burning/itching at application site · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…

Topical calcineurin inhibitors: tacrolimus 0.1% ointment showed no clear difference in primary: adverse events ‐ burning/itching at application site compared with vehicle (moderate certainty).

1 finding from 1 review

Tacrolimus 0.1% vs vehicle

Secondary: investigator‐rated reduction in severity ‐ Not measured · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…

The review found no eligible studies for this question.

1 finding from 1 review

Tacrolimus 0.03% vs corticosteroids

Physician's assessment of global response of improvement, clear or excellent ‐ 6 weeks · people with atopic dermatitis

Tacrolimus 0.03% probably leads to higher physician's assessment of global response of improvement, clear or… compared with corticosteroids (moderate certainty).

4 findings from 1 review
Show 1 more finding

Moderate‐potency vs mild‐potency topical corticosteroid

Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time within 1‐5 weeks) · children and adults with mild to severe eczema

Moderate‐potency probably leads to higher clinician‐reported signs of eczema: IGA (number with cleared or… compared with mild‐potency topical corticosteroid (moderate certainty).

1 finding from 1 review

Potent vs moderate‐potency topical corticosteroid

Patient‐reported symptoms of eczema · children and adults, most with moderate to severe eczema

Potent may leads to lower patient‐reported symptoms of eczema: PGA; short‐term (week 1) compared with moderate‐potency topical corticosteroid (low certainty).

1 finding from 1 review

Very potent vs potent topical corticosteroid

Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time point within 1‐2 weeks) · adults with eczema

Very potent showed no clear difference in clinician‐reported signs of eczema: IGA (number with cleared or… compared with potent topical corticosteroid (low certainty).

1 finding from 1 review

Very potent vs potent topical corticosteroid

Local adverse events: skin thinning; end of treatment (1 to 3 weeks) · adults with eczema

It is very uncertain whether very potent changes local adverse events: skin thinning; end of treatment (day 11‐day 22) compared with potent topical corticosteroid (very low certainty).

1 finding from 1 review

Twice daily or more vs once daily topical corticosteroid

Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time point within 1‐4 weeks) · children and adults, most with moderate to severe eczema

Twice daily or more showed no clear difference in clinician‐reported signs of eczema: IGA (number with cleared or… compared with once daily topical corticosteroid (moderate certainty).

1 finding from 1 review

Twice daily or more vs once daily topical corticosteroid

Patient‐reported symptoms of eczema · children and adults, most with moderate to severe eczema

Twice daily or more showed no clear difference in patient‐reported symptoms of eczema: PGA (number with cleared or… compared with once daily topical corticosteroid (low certainty).

1 finding from 1 review